Double-A Day: Apple, Amazon Earnings Awaited After Close To Cap Historic Month

 | Apr 30, 2020 12:24PM ET

Earlier in April, stocks had their best week since 1974. Barring a major setback today, they {{0|now}} have a chance for the best month since 1974.

It’s amazing to think we’ve had gains not seen in 46 years when just last month was the kind you hope doesn’t happen for at least another 46 years. Stocks have a weaker tone this morning as investors contemplate another awful jobless claims number, however (see more below).

Who would have thought on April 1 that the S&P 500 Index would rally like this over the next 29 days when it had just fallen 4% to start the new month after one of the worst months in its history? As it turned out, the April 1 low just under 2450 was the low for the calendar page as April recorded nearly 14% gains from the end of March through yesterday’s close.

A lot of this likely reflects what appears to be a pretty solid floor put under the market by the kind of fiscal and monetary policy response not seen in any previous crisis. Congress and the Fed arguably deserve a lot of the credit for this incredible turnaround. Hopes for a virus treatment also play into the April optimism.

Yesterday’s Fed meeting underscored what obviously continues to be a really impressive effort to lend the economy some belts and suspenders in this unprecedented situation. The meeting concluded without a policy change but with the Fed pledging to keep rates at zero until the U.S. is back on track toward full employment and inflation. The way things are going, that could be a long time, something Fed Chairman Jerome Powell made clear in his press conference.

Amazon, Apple Step Into Batter’s Box (NYSE:BOX)

It won’t be a long time, however, before investors get a look at quarterly results from two of the most closely followed stocks on Wall Street. Apple (NASDAQ:AAPL) and Amazon (NASDAQ:AMZN) both report after the close today, potentially giving a closer look at how supply chains in China and consumer demand for the latest electronic gizmos and home shopping are doing in the time of coronavirus. Today is the busiest earnings day of the busiest earnings week of the quarter.

Investors are likely to closely monitor details of Amazon Web Services (AWS), a business of Amazon’s that seems tailor-made for the internet-centric work-and-play-at-home economy. Apple was among the hardest-hit firms when coronavirus began to unfold starting late last year. It’s lost significant revenue with stores closed in the U.S. since early March. Consider watching closely for any iPhone updates, particularly for signs of supply chain delays hurting production.

Earnings news didn’t stop last night after the close. Microsoft (NASDAQ:MSFT), Facebook (NASDAQ:FB) and Tesla (NASDAQ:TSLA) all saw shares move higher as investors surveyed their results. Microsoft’s cloud business flourished in its latest quarter, which could bode well for Amazon later today. The company’s Azure cloud services revenue rose 59%. Tesla (NASDAQ:TSLA) managed to surprise with a small quarterly profit, and Facebook easily beat Wall Street’s estimates as ad revenue held up well despite the economic crisis.

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

The shutdown took a toll on McDonald’s (NYSE:MCD), however. The company missed analysts’ earnings projections and same-store sales fell more than 3% in Q1. Revenue did beat Wall Street’s estimates, but shares fell about 1% in pre-market trading. McDonald's more than most companies showed the dramatic effect of COVID-19. The CEO said they were off to a great year after a really good 2019 and had a lot of momentum before the virus pulled the floor out from under them.

Twitter (NYSE:TWTR) shares went back and forth between this morning in pre-market trading as investors pondered mixed news from the company’s earnings report. Recently shares fell nearly 5%. Ad revenue fell once the virus hit, but user data looked good. The company wants to build infrastructure to keep up with demand, which is great, but supply chain constraints could affect the build-out.

In other morning developments, the European Central Bank (ECB) kept rates unchanged despite a 3.8% drop in economic growth in Q1. The ECB already delivered a ton of stimulus earlier in the crisis.

U.S. weekly new jobless claims reached 3.84 million, higher than the average analyst estimate of 3 million. This could seem to be putting a damper on some of the leftover enthusiasm from yesterday’s rally. More than 30 million Americans have lost their jobs since this crisis started. It’s an unbelievable number that speaks to the human toll of this pandemic.

Personal spending fell 7.5% in March, the government said this morning, the worst drop since records began in this category back in 1959. Personal consumption expenditure prices fell 0.3% in March. This is the Fed’s favored inflation gauge.

Trust But Verify

As we noted recently, investors are looking for any “light at the end of the tunnel.” While it’s nice to be optimistic, basing your investment strategy on “hope” isn’t necessarily the best idea.

Take yesterday’s news of positive results in trials of Gilead's (NASDAQ:GILD) drug to treat coronavirus. The first headlines came out minutes before the market opened, and the {{169|Dow Jones Industrial Average}} quickly bounded higher when trading started. The futures market had indicated gains of about 200 points, but the Gilead news helped send the Dow up more than 500 shortly after the opening bell. There was no other major news at the time that could have explained this quick shot higher.

This shot in the arm for the Dow speaks to euphoria about possible good news, and investors can’t be blamed for getting excited. That said, if you know how medical trials work, it’s not necessarily the panacea some might think. A lot more studying is still ahead, though it was good to see data presented yesterday from the National Institute of Allergy and Infectious Diseases that showed the mortality rate trended “towards being better” among patients who took the drug vs. those who didn’t.

If you’ve traded biotech stocks in the past, you probably know the winding path these trials sometimes go through before a drug becomes widely used. This situation is a little different due to the nature of the emergency, so it’s possible Remdesivir could have a more immediate impact. The lesson here for investors is to trust but verify, as President Ronald Reagan once told Soviet leader Gorbachev.

Most of Market Riding the Rally Train

The positive drug trial news yesterday, along with hopes of economic reopening, injected optimism as once again, small- and mid-cap stocks outplayed the large-cap ones to finish higher on the leaderboard. Yesterday’s rally was widespread across most sectors and included the vast majority of stocks in the SPX (NYSE:SPXC). That’s what bullish investors want to see more of if it’s truly a healthy rally, rather than having just a few heavyweights take the indices higher while most stocks tread water.

Not to burst any balloons, but today is the last day of the month and sometimes that can mean profit taking. Investors might want to consider taking a bit more care than usual venturing into the market with the end of the month looming. Also, you could argue that the stock market has come a very long way, very quickly. There’s still a chance stocks could start getting tripped up by all the negative data as the new month gets underway.

From a technical standpoint, the SPX is approaching its 200-day moving average again. That key resistance point lies just above the 3000 mark, a level where the SPX hasn’t traded in nearly two months.